
Medigene AG
Medigene AG (MDGEF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MDGEF · as of Jun 15, 2026
Key Statistics
Explore Medigene AG Data
mdgef stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
mdgef competitorsStock Performance
Full HistoryAbout Medigene AG
Medigene AG is a biotechnology firm dedicated to advancing T-cell immunotherapies for the treatment of cancer. The company's core therapeutic focus involves the development of personalized T-cell-base…
what is medigene ag · mdgef stock overview · medigene ag company profile · who is medigene ag ceo · mdgef OTC · medigene ag headquarters · medigene ag business segments
About Stock Overview & Key Data
Medigene AG (MDGEF) is a Healthcare company in the Biotechnology industry, listed on OTC since Jun 17, 2013. As of the latest trading session, MDGEF stock price is $2.59, with a market capitalization of $38.2M. The stock has returned +0.00% over the past 12 months and +0.00% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Medigene AG stock is Buy, with an average 12-month price target of $—. In fiscal year 2023, Medigene AG reported revenue of $6.0M and net income of -$16.2M. For detailed data — including Medigene AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Medigene AG (MDGEF) stock price is $2.59. The stock is traded on OTC under the ticker symbol MDGEF. The 52-week range is $0.10 – $2.59.